Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dale Schenk

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Neuron|November 7, 2025
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson's DiseaseEliezer Masliah, Edward Rockenstein, Anthony Adame, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 16, 2013
Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalitiesWagner Zago, Sally Schroeter, Teresa Guido, et al.
Neuron|June 15, 2005
Effects of alpha-synuclein immunization in a mouse model of Parkinson's diseaseEliezer Masliah, Edward Rockenstein, Anthony Adame, et al.
Plos One|January 10, 2013
AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrilsJonathan S Wall, Stephen J Kennel, Angela Williams, et al.
The American Journal of Pathology|January 15, 2013
Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synucleinDora Games, Peter Seubert, Edward Rockenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?Michael Grundman, Ronald C Petersen, David A Bennett, et al.
Alzheimer Disease and Associated Disorders|February 24, 2006
The role of biomarkers in clinical trials for Alzheimer diseaseLeon J Thal, Kejal Kantarci, Eric M Reiman, et al.
Frontiers in Immunology|May 9, 2012
Generation and characterization of anti-AA amyloid-specific monoclonal antibodiesJonathan S Wall, Stephen J Kennel, Tina Richey, et al.
Human Molecular Genetics|July 16, 2004
Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpressionJoseph Krezowski, Danielle Knudson, Christine Ebeling, et al.
Acta Neuropathologica Communications|March 27, 2026
Retraction Note: Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathyBrian Spencer, Elvira Valera, Edward Rockenstein, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Neuron|November 7, 2025
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson's DiseaseEliezer Masliah, Edward Rockenstein, Anthony Adame, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 16, 2013
Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalitiesWagner Zago, Sally Schroeter, Teresa Guido, et al.
Neuron|June 15, 2005
Effects of alpha-synuclein immunization in a mouse model of Parkinson's diseaseEliezer Masliah, Edward Rockenstein, Anthony Adame, et al.
Plos One|January 10, 2013
AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrilsJonathan S Wall, Stephen J Kennel, Angela Williams, et al.
The American Journal of Pathology|January 15, 2013
Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synucleinDora Games, Peter Seubert, Edward Rockenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?Michael Grundman, Ronald C Petersen, David A Bennett, et al.
Alzheimer Disease and Associated Disorders|February 24, 2006
The role of biomarkers in clinical trials for Alzheimer diseaseLeon J Thal, Kejal Kantarci, Eric M Reiman, et al.
Frontiers in Immunology|May 9, 2012
Generation and characterization of anti-AA amyloid-specific monoclonal antibodiesJonathan S Wall, Stephen J Kennel, Tina Richey, et al.
Human Molecular Genetics|July 16, 2004
Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpressionJoseph Krezowski, Danielle Knudson, Christine Ebeling, et al.
Acta Neuropathologica Communications|March 27, 2026
Retraction Note: Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathyBrian Spencer, Elvira Valera, Edward Rockenstein, et al.
Pageof 7